He—Ne激光治疗声带小结的机理研究

我院应用He－Ne激光治疗551例声带小结，取得较好疗效。为研究作用机理，我们进行了免疫功能测定、测温试验、He－Ne激光照射前后的间接喉镜检查、显微结构研究、抑菌试验和过氧化脂质测定。结果提示He－Ne激光照射治疗声带小结的机理为照射后喉部温度升高、血管扩张、血循环加快，从而增强局部营养，促进喉部粘膜生长、消除组织水肿，加速炎性渗出物和毒素的排泄。而He－Ne激光本身没有杀菌和抑菌作用。     

33例肝占位性病变MRI误诊的分析

我院１９８８年以来４０００余例腹部ＭＲＩ中，发现肝占位性病变误诊３３例。所用机型为美国Ｄｉｓｏｎｉｃｓ公司０．５Ｔ超导ＭＲＩ，自旋回波序列（ＳＥ序列）、常规Ｔ１加权（Ｔ１ＷＩ）、质子加权（ＰＤＷＩ）、Ｔ２加权（Ｔ２ＷＩ），覆盖全肝。其中，ＰＨＣ误诊为ＭＨＣ５例、ＭＨＣ误诊为ＰＨＣ６例、ＰＨＣ误为ＨＨＥ５例、ＭＨＣ误诊为ＨＨＥ２例、ＨＨＥ误诊为ＰＨＣ６例、肝硬化结节误诊为ＰＨＣ２例、炎性假瘤误诊为ＰＨＣ３例、肝结核误诊为ＰＨＣ１例、ＨＣＹ误诊为ＨＨＥ３例。本文从病变的影像学特征和扫描技术方面详细探讨了误诊的原因和鉴别诊断要点。     

雷公藤挥发油对小鼠免疫功能的影响

观察雷公藤挥发油对小鼠免疫功能的影响,发现给药1周后,其可减少脾脏有核细胞数,减少 PFC 和 RFC 数目,抑制脾细胞对 ConA 诱导 T 细胞增殖的反应性,减轻DTH。这说明雷公藤挥发油对小鼠体液免疫和细胞免疫均有明显的抑制作用。     

火器伤后胸心异物存留

目的：探讨火器伤后胸心异物存留摘除的指征、时机、方法及结果。方法：回顾性分析了３９例火器伤后胸心异物存留摘除者的一般资料、临床表现、不同处理方法的选择及效果。结果：１９例患者早期因凝固性血胸及肺持续漏气伴异物存留或异物存留伴胸腔及心包腔化脓性感染，在开胸清创时做了异物摘除；另２０例患者为胸伤伤情恢复后单纯异物存留，因异物位于肺门、心脏及大血管旁或远期并发症等，而后期开胸异物摘除。结论：火器性胸部穿透伤后，因异物本身或其他原因所致早期并发症者，应在开胸清创的同时摘除异物；胸伤伤情恢复而单纯胸心异物存留，应选择性摘除或因并发远期并发症而摘除。     

冠心病、高脂血症和低高密度脂蛋白血症患者载脂蛋白Al基因的多态性

本实验用分析基因限制性内切酶片段长度多态性(Restriction fragment length olymorphisms,RFLPs)技术,检测到中国人载脂蛋白AI(Apolipoprotein AI。Apo AI)基因3′端存一PstI多态位点,并发现该多态位点与低高密度脂蛋白(HDL)血症及冠心病有较密切的关系。     

人胎儿胃液、胆汁及胃粘膜、胆囊组织胃动素水平及其相关性

作者采用特异性胃动素(MTL)抗体,通过放射免疫法,对8例16～40周龄的人胎儿胃液、胆汁及胃粘膜、胆囊组织MTL含量进行探测。结果显示:MTL含量胃液为46.00±12.87pmol/L,胆汁为29.89±15.45Pmol/L;胃粘膜为1.34±0.45pmol/g,胆囊为0.87±0.32pmol/g.胃液、胃粘膜MTL含量分别高于胆汁及胆囊MTL水平(P<0.05)。相关分析显示:胃液与胃粘膜MTL含量,胆汁与胆囊MTL含量均呈显著正相关(N=8,r=0.8933,P<0.01;N=8,r=0.9016,P<0.01)。胃粘膜MTL含量与胎龄增长也呈显著正相关(N=8,r=0.7321,P<0.05)。     

锁骨下动脉狭窄或闭锁的治疗

用经皮经腔动脉成形术（ＰＴＡ）治疗锁骨下动脉狭窄或闭锁２４例，用血管旁路术治疗１４例。结果：２种治疗方法的近期通畅率相似，２年通畅率分别为６６．７％和７２．７％。提示：ＰＴＡ和血管旁路术均是治疗锁骨下动脉狭窄或闭锁的有效方法     

预防肝硬化上消化道出血的临床研究

目的　探讨普萘洛尔和低剂量兰索拉唑长期维持治疗对预防肝硬化门脉高压消化道出血的疗效。方法　1 1 9例肝硬化门脉高压患者随机分为 3组 :Ⅰ组 :给予口服普萘洛尔加上护肝治疗。Ⅱ组 :联合给予低剂量兰索拉唑和普萘洛尔。Ⅲ组 :仅给予护肝治疗。兰索拉唑维持服药 6个月 ,普萘洛尔及一般对症治疗维持 1年。观察治疗前后各组患者所伴发溃疡、门脉高压性胃病 (PHG)、急性胃黏膜病变 (AGML)情况 (发生率 ) ,各组消化道出血的复发率、门静脉直径 (PVD)、脾静脉直径 (SVD)的变化。结果　经 1年观察 ,结果显示 ,普萘洛尔组、联合治疗组、对照组出血的复发率分别为 1 5 0 %、2 2 %、48 5 % ,组Ⅰ、组Ⅱ复发率显著低于组Ⅲ ,同时 ,组Ⅰ与组Ⅱ间的差异有显著性意义。治疗可见组Ⅰ、组Ⅱ患者所伴发的溃疡、PHG、AGML明显改善 ,PVD、SVD缩小。结论　普萘洛尔组联合抑制酸维持治疗 ,可预防引起消化道出血多种病因 ,较单用普萘洛尔的疗效好     

Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma.

The pharmacokinetics and pharmacodynamics of mitoxantrone were studied in 15 patients with advanced nasopharyngeal carcinoma (NPC) after single intravenous rapid infusion (12 to 14 mg/m2). Mitoxantrone plasma concentrations and urinary excretion were measured specifically with the use of a high-performance liquid chromatographic method with ultraviolet detection at 242 and 658 nm. The pharmacokinetic parameters are described adequately by a three-compartment model with a terminal half-life of 71.5 +/- 40.1 hours and a volume of distribution of 5037 +/- 2377 l. The total plasma clearance was 743 +/- 462 ml/minute, and the renal clearance was 18.8 +/- 8.49 ml/minute. Within 72 hours, 1.8 +/- 0.6% of the administration dose was excreted in urine as mitoxantrone parent compound. From the urinary excretion rate data, glomerular filtration and possible tubular reabsorption were the mechanisms involved in the urinary excretion of mitoxantrone. The values for unbound fraction (%) in plasma at time 0 and 5 minutes were 2.88 +/- 0.91% and 3.25 +/- 1.19%, with an average of 3.04 +/- 1.01%. The degree of protein binding of mitoxantrone was not affected by concentration (P greater than 0.05) in Chinese patients with NPC. The response rate for mitoxantrone was poor in this study. Clinical studies have demonstrated that mitoxantrone was generally well tolerated. Only very low incidences of nausea, vomiting, and alopecia were observed. The mild and rapidly reversible dose-limiting hematologic toxic effects have proven leukopenia. Although the toxicities reported here were tolerated for most patients, other combination regimens including mitoxantrone or other administration routes may be considered and need to be evaluated carefully.